Several studies reported that CRISPR system-mediated modifications of multiple resistance-related genes resulted in the alleviated resistance to cisplatin, including excision repair cross-complementation group 1 (ERCC1), ribosomal protein S6 kinase 4 (RSK4), NRF2, and nicotinamide nucleotide transhydrogenase (NNT) in NSCLC (Heyza et al., 2019; Chrysostomou et al., 2021; Banas et al., 2022; Xu et al., 2023). This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.